Elezanumab

Research use only, not for human use.

Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, with an IC50 of approximately 97 pM.

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism.

——

Animal Model:Female Lewis rat optic neuritis modelsDosage:1, 3, or 10 mg/kg Administration:IV; once a week for 5 doses Result:Protected against the optic nerve inflammationinduced RNFL degeneration.Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg

——

Others

Other Targets

TGF-beta/Smad

——

——

1791416-49-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years